Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer

被引：28

作者：

Wang, Wenxian ^{[1
,2
,3
]}

Huang, Zhangzhou ^{[4
]}

Yu, Zongyang ^{[5
]}

Zhuang, Wu ^{[4
]}

Zheng, Weijun ^{[6
]}

Cai, Zhijian ^{[7
]}

Shi, Lei ^{[8
]}

Yu, Xinmin ^{[1
,2
,3
]}

Lou, Guangyuan ^{[1
,2
,3
]}

Hong, Wei ^{[1
,2
,3
]}

Zhang, Yiping ^{[1
,2
,3
]}

Chen, Ming ^{[9
]}

Song, Zhengbo ^{[1
,2
,3
]}

机构：

[1] Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China

[2] Zhejiang Canc Hosp, Hangzhou, Peoples R China

[3] Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China

[4] Fujian Med Univ, Fujian Prov Canc Hosp, Dept Med Oncol, Canc Hosp, Fuzhou, Peoples R China

[5] 900th Hosp, Dept Med Oncol, Fuzhou, Peoples R China

[6] Zhejiang Chinese Med Sch, Coll Publ Hlth, Dept Med Stat, Hangzhou, Peoples R China

[7] Zhejiang Univ, Inst Immunol, Sch Med, Hangzhou, Peoples R China

[8] Hangzhou YITU Healthcare Technol Co Ltd, Hangzhou, Peoples R China

[9] Zhejiang Canc Hosp, Zhejiang Key Lab Radiat Oncol, Hangzhou, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2020年 / 10卷

基金：

中国国家自然科学基金;

关键词：

immune checkpoint inhibitor; non-small cell lung cancer; biomarker; chemotherapy; lung immune prognostic index; TO-LYMPHOCYTE RATIO; SERUM LACTATE-DEHYDROGENASE; EARLY MARKER; OPEN-LABEL; NSCLC; OUTCOMES; PEMBROLIZUMAB; ASSOCIATION; THERAPY; IMMUNOTHERAPY;

D O I：

10.3389/fonc.2020.572853

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Lung immune prognostic index (LIPI) status was recently developed to predict responses to immune checkpoint inhibitor (ICI) treatments. However, it is unclear whether LIPI is a prognostic index for both patients treated with ICI monotherapy and patients treated with ICIs combined with chemotherapy (ICIs CC). Methods This retrospective study established the patterns of LIPI in Chinese patients with advanced non-small cell lung cancer. Lung immune prognostic index based on the derived neutrophil-to-lymphocyte ratio greater than 3 and lactate dehydrogenase greater than the upper limit of normal was developed to characterize good, intermediate, or poor LIPI status. Associations between LIPI status and progression-free survival (PFS) and overall survival (OS) were analyzed. Kaplan-Meier curves and Cox proportional hazards models were used to determine survival differences. Results Three hundred thirty patients were included in this study. Of these patients, 216 received ICI monotherapy and 114 received ICIs CC. A good LIPI status was associated with better PFS (6.1 months vs. 2.3 months vs. 2.1 months, P = 0.023) and OS (24.2 months vs. 14.5 months vs. 9.3 months, P < 0.001) in ICI monotherapy compared to intermediate or poor LIPI status. No differences in PFS (17.9 vs. 9.9 months vs. 7.6 months, P = 0.355, respectively) and OS (P = 0.346) were observed in patients who received ICIs CC. Moreover, we found that patients who had an improved LIPI status compared with the baseline value had a longer PFS with ICI monotherapy and LIPI intermediate status (8.4 months vs. 2.1 months vs. 1.4 months, P < 0.001). However, in patients treated with ICIs CC, these dynamic changes were not observed (P = 0.444). Conclusions Lung immune prognostic index status and dynamic changes in LIPI could be prognostic markers of treatment response to ICI monotherapy, but not to ICIs CC. In particular, good LIPI status was associated with a better clinical outcome compared with intermediate and poor LIPI status in ICI monotherapy treatment.

引用

页数：11

共 45 条

[1] The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors [J].

Benitez, Jose C. ;

Recondo, Gonzalo ;

Rassy, Elie ;

Mezquita, Laura .

QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 64 (02) :162-174

[2]

Blanc-Durand F, 2019, ANN ONCOL, V30, P5

[3] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population [J].

Brzezianska, Ewa ;

Karbownik, Malgorzata ;

Migdalska-Sek, Monika ;

Pastuszak-Lewandoska, Dorota ;

Wloch, Jan ;

Lewinski, Andrzej .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) :26-35

[4] Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non-Small Cell Lung Cancer [J].

Corredor, German ;

Wang, Xiangxue ;

Zhou, Yu ;

Lu, Cheng ;

Fu, Pingfu ;

Syrigos, Konstantinos ;

Rimm, David L. ;

Yang, Michael ;

Romero, Eduardo ;

Schalper, Kurt A. ;

Velcheti, Vamsidhar ;

Madabhushi, Anant .

CLINICAL CANCER RESEARCH, 2019, 25 (05) :1526-1534

[5] Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma [J].

Diem, S. ;

Kasenda, B. ;

Spain, L. ;

Martin-Liberal, J. ;

Marconcini, R. ;

Gore, M. ;

Larkin, J. .

BRITISH JOURNAL OF CANCER, 2016, 114 (03) :256-261

[6] Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab [J].

Diem, Stefan ;

Schmid, Sabine ;

Krapf, Mirjam ;

Flatz, Lukas ;

Born, Diana ;

Jochum, Wolfram ;

Templeton, Arnoud J. ;

Fruh, Martin .

LUNG CANCER, 2017, 111 :176-181

[7] Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab [J].

Ferrucci, P. F. ;

Ascierto, P. A. ;

Pigozzo, J. ;

Del Vecchio, M. ;

Maio, M. ;

Cappellini, G. C. Antonini ;

Guidoboni, M. ;

Queirolo, P. ;

Savoia, P. ;

Mandala, M. ;

Simeone, E. ;

Valpione, S. ;

Altomonte, M. ;

Spagnolo, F. ;

Cocorocchio, E. ;

Gandini, S. ;

Giannarelli, D. ;

Martinoli, C. .

ANNALS OF ONCOLOGY, 2016, 27 (04) :732-738

[8]

Fiala O, 2016, ANTICANCER RES, V36, P2459

[9] Immunological Mechanisms Underneath the Efficacy of Cancer Therapy [J].

Galluzzi, Lorenzo ;

Zitvogel, Laurence ;

Kroemer, Guido .

CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11) :895-902

[10] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

← 1 2 3 4 5 →